PEG Nanocarriers, Nanogels and Synthesis Methods




Invention Summary:

A novel platform of PEG-only nanocarriers and nanogels has been developed by Rutgers scientists. The nanocarriers range from 100Da-100kDa and are capable of forming stable nanogels and nanogel aggregates in a variety of sizes from 20-30nm up to greater than 1000nm. The carriers and gels have improved solubility over existing technologies and provide for enhanced loading of drug agents. Several methods have been developed to create and tailor a wide variety of polymers and copolymers utilizing an assortment of cross-linkers and functional groups to alter surface charge, charge density, hydrophobicity, cell and tissue interactions and trafficking. Collectively, the characteristics of this novel class of PEG-based nanocarriers, nanogels and nanogel aggregates enable delivery of agents requiring higher dosing and with solubility limitations, and provide for target delivery to the site of action.


Market Applications:

Therapeutics, Diagnostics, Imaging, Drug Delivery, Polymer, PEG.

Advantages:

Increased drug loading to overcome conjugation effects of lower potency drugs, enhanced local and minimized systemic delivery of drugs, improved solubility of drugs.

Development Status:

Provisional patent application filed. IP claims compounds and synthesis methods.



Patrick J. Sinko, PhD.
Managing Director
Rutgers, the State University of New Jersey
Patrick J. Sinko is Associate Vice President for Research. He holds the Parke-Davis Endowed Chair in Pharmaceutics and Drug Delivery. Dr. Sinko is Professor II (Pharmaceutics) and adjunct professor in the Rutgers Business School. As Associate Vice President for Research, he is charged with promoting Rutgers research, facilitating research commcerialization, synergizing research collaborations, and technology transfer with faculty through the Office of Research and Sponsored Programs (ORSP) and the Office of Technology Commercialization (OTC). Dr. Sinko's research is focused on the mechanisms and applications of biopharmaceutics and polymers to drug delivery and targeting. His laboratory is located in the Ernest Mario School of Pharmacy. His group's research efforts focus on the design, fabrication and evaluation of molecular-scale drug and diagnostic delivery technologies applied broadly to asthma, AIDS, chemical counterterrorism, and cancer.